Gefitinib: An effective Treatment
Created 5 months ago by anniepery

Gefitinib specifically is the first approved selective inhibitor of epidermal growth factor receptor's (EGFR) tyrosine kinase domain. This interaction of apatinib plus gefitinib is expected to be established a new first-line treatment option for patients with EGFR-mutant NSCLC. The initial level trials were conducted on 313 patients. One 250 mg tablet of gefitinib should be taken once a day. In case of any particular missed dose, it should be administered promptly as the patient remembers. You can purchase gefitinib tablets ip 250 mg online or from any certified pharmacy.